Strumento inattivo

Azioni Biondvax Pharmaceuticals Ltd

Azioni

Prezzo di chiusura TEL AVIV STOCK EXCHANGE Altri mercati azionari
- ^ILa	-

Biondvax Pharmaceuticals : Announces Rights Offering Fully Subscribed at US$20 Million	16/07/19
Biondvax Pharmaceuticals : First Participant Enrolled in Second Cohort of BiondVax’s Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial	08/07/19
Biondvax Pharmaceuticals : European Investment Bank VP attends Signature Event at BiondVax Extending Financing Agreement with BiondVax to €24 million	26/06/19
Biondvax Pharmaceuticals : Patent Covering Manufacturing Process of BiondVax’s M-001 Universal Flu Vaccine Allowed in USA and Japan	18/06/19
Biondvax Pharmaceuticals : Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process	10/06/19

Dirigenti	Titolo	Età	Da
Amir Reichman CEO	Chief Executive Officer	49	02/03/21
Uri Ben-Or DFI	Director of Finance/CFO	52	01/01/07
Dalit Weinstein Fischer CTO	Chief Tech/Sci/R&D Officer	-	01/01/22

Amministratori	Titolo	Età	Da
Adi Raviv BRD	Director/Board Member	69	24/03/20
Samuel Moed BRD	Director/Board Member	62	24/03/20
Morris Laster BRD	Director/Board Member	60	27/11/17

Settore

	Variaz. 1 gen.	Capi.
MODERNA, INC.	+29,37%	49,18 Mrd
IQVIA HOLDINGS INC.	+1,02%	42,11 Mrd
LONZA GROUP AG	+50,47%	40,37 Mrd
CELLTRION, INC.	-5,26%	28,85 Mrd
ICON PUBLIC LIMITED COMPANY	+13,68%	26,09 Mrd
ALNYLAM PHARMACEUTICALS, INC.	-22,65%	18,71 Mrd
BIO-TECHNE CORPORATION	+8,10%	13,26 Mrd
MEDPACE HOLDINGS, INC.	+32,23%	12,32 Mrd
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0,91%	11,99 Mrd